Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Moderna Inc (NQ: MRNA )

54.63 +0.27 (+0.50%)
Official Closing Price Updated: 4:15 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Moderna Inc

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Novavax Stock Rocketed This Year, But Challenges Persist. Is It A Buy Or A Sell?
Its 12-month relative strength performance is impressive, but Novavax now faces resistance. 
Via Investor's Business Daily
Rosen Law Firm Urges Moderna, Inc. (NASDAQ: MRNA) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
MODERNA, INC. (NASDAQ: MRNA) INVESTOR ALERT: Investors With Large Losses in Moderna, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
From Bernstein Liebhard LLP
Via GlobeNewswire
FDA Set To Approve COVID-19 Vaccines As Soon As This Week: Stocks, ETFs To Watch
The FDA may approve updated COVID-19 vaccines this week to combat recent strains as the country endures a significant summer outbreak. 
Via Benzinga
Topics ETFs
Exposures COVID-19 Product Safety
Demystifying Moderna: Insights From 11 Analyst Reviews
Via Benzinga
Moderna and Coursera Launch Free Course on mRNA Technology
Via ACCESSWIRE
Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
Biotechnology company Moderna Inc. (NASDAQ: MRNA) stock rocked investors with a 30% drop following its second-quarter 2024 earnings release. 
Via MarketBeat
Exposures COVID-19 Product Safety
Pfizer and BioNTech's Combo Shot Missed the Mark. Is It Time to Sell?
A clinical-trial failure for Pfizer and BioNTech means Moderna is leading the race to develop a combo shot for the flu and COVID-19. 
Via The Motley Fool
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Moderna and Sprinklr and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Smart Money Is Betting Big In MRNA Options
Via Benzinga
Market Whales and Their Recent Bets on MRNA Options
Via Benzinga
What the Options Market Tells Us About Moderna
Via Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth $6,300 Today
Via Benzinga
MRNA Shareholder Notice: Robbins LLP Reminds Investors of the Class Action Filed Against Moderna, Inc.
From Robbins LLP
Via Business Wire
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Moderna, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRNA
From The Rosen Law Firm PA
Via GlobeNewswire
Pfizer, BioNTech's COVID-19/Flu Combo Vaccine Fails To Meet Key Goal In Late-Stage Study
Pfizer and BioNTech report Phase 3 results for their combined mRNA vaccine against influenza and COVID-19. The trial met one of two primary immunogenicity objectives. Adjustments are planned to improve... 
Via Benzinga
Exposures COVID-19
MRNA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Moderna, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
MODERNA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Moderna, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Stockholder Alert: Robbins LLP Informs Moderna, Inc. Stockholders that a Shareholder Filed a Class Action Against MRNA
From Robbins LLP
Via Business Wire
Stockholder Alert: Robbins LLP Informs Moderna, Inc. Stockholders that a Shareholder Filed a Class Action Against MRNA
From Robbins LLP
Via GlobeNewswire
MRNA Investors Have Opportunity to Lead Moderna, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
Struggling COVID-19 Vaccines From AstraZeneca, BioNTech/Pfizer, Moderna Cut Incidence Of Arterial Thromboses That Cause Heart Attacks, Strokes, British Study Shows
COVID-19 vaccinations could lower the incidence of heart attacks and strokes, according to a new study by UK universities. The research shows a significant reduction in cardiovascular events among... 
Via Benzinga
Exposures COVID-19
Long Covid Remains Diagnostic Mystery, Diagnosis Remains Elusive; National Institutes of Health-Funded Study Shows
A recent NIH study reveals no clear diagnostic test for Long Covid, highlighting ongoing challenges in identifying and treating the condition affecting millions of Americans. Researchers continue to... 
Via Benzinga
Exposures COVID-19
3 Biotech Stocks Poised for a Comeback After Last Week’s Market Meltdown
Investors should closely watch these three biotech stocks as their strong prospects are likely to help the rebound from market volatility. 
Via InvestorPlace
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Moderna, Inc. Investors With Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – MRNA
From The Rosen Law Firm PA
Via GlobeNewswire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Novavax Plunges on Earnings Miss: Falling Knife or Buying Opp?
Novavax Inc. (NASDAQ: NVAX) is a biotechnology company that focuses on developing and commercializing vaccines for serious infectious diseases. 
Via MarketBeat
Exposures COVID-19
MRNA Investors Have Opportunity to Lead Moderna, Inc. Securities Fraud Lawsuit with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Expanding the Cloud for AI
Amazon, Alphabet, Microsoft, and Meta are all spending a ton of money to build out cloud capabilities to fuel the next phase of AI growth. But the market isn't sold on that spend yet. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.